A phase II study of anti-angiogenesis therapy for metastatic melanoma using ABT-510.
Phase of Trial: Phase II
Latest Information Update: 13 May 2011
At a glance
- Drugs ABT 510 (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 16 Feb 2011 Actual end date (Jun 2005) added as reported by ClinicalTrials.gov.
- 16 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.